Cancerous disease modifying antibodies
A technology of antibodies and chimeric antibodies, applied in allergic diseases, antibodies, radioactive carriers, etc., can solve problems such as insufficient cancer
Image
Examples
Embodiment 1
[0127] Hybridoma production----hybridoma cell line AR90A56.11
[0128] According to the Budapest Treaty, the hybridoma cell line AR90A56.11 was deposited in the International Depository of Canada (the International Depository Authority of Canada, IDAC) on December 5, 2006, and the Bureau of Microbiology, Health Canada (Bureau of Microbiology, HealthCanada) (Canada, Ma 1015 Arlington Street, Winnipeg, Nitoba, R3E 3R2) with accession number 051206-03. Pursuant to 37 CFR 1.808, the depositor warrants that, at the time of grant of the patent, all constraints imposed on the public availability of the deposited material are irrevocable. If the depositary cannot release a viable sample, replace the deposit.
[0129] To generate hybridomas producing anticancer antibody AR90A56.11, single cell suspensions of frozen lung adenocarcinoma tumor tissue (Genomics Collaborative, Cambridge, MA) were prepared in PBS. Prepare IMMUNEASY by mixing gently TM(Qiagen, Venlo, The Netherlands) adjuv...
Embodiment 2
[0136] in vitro binding
[0137] AR90A56.11 monoclonal antibody was produced by growing hybridomas in CL-1000 flasks (BD Biosciences, Oakville, ON), harvested and reseeded twice / week. Standard antibody purification steps were followed using Protein G Sepharose 4 Fast Flow (Amersham Biosciences, Baie d'Urfe, QC). It is within the scope of the invention to use deimmunized, humanized, chimeric or murine monoclonal antibodies.
[0138] Association of AR90A56.11 with lung (A549, NCI-H23, NCI-H322M, NCI-H460, and NCI-H520), colon (Lovo), breast (MDA-MB-231), pancreas, Combination of (BxPC-3), prostate (PC-3) and ovarian (OVCAR-3) carcinomas, and non-cancer cell lines from skin (CCD-27sk) and lung (Hs888.Lu). All cell lines, except the lung cancer cell line NCI-H322M, were obtained from the American Type Tissue Collection (ATCC, Manassas, VA). NCI-H322M was obtained from the NCI-Frederick Cancer DCTD Tumor / Cell Line Repository (Frederick, MD).
[0139] By initially using DPBS (Ca...
Embodiment 3
[0142] In vivo tumor experiments using BxPC-3 cells
[0143] Examples 1 and 2 demonstrate that AR90A56.11 has anticancer properties against human cancer cell lines with detectable binding to several different cancer indicators. refer to Figure 4 and 5 , 8-10 week old female SCID mice were implanted with 5 million human pancreatic cells (BxPC-3) in 100 microliters of PBS solution by subcutaneous injection at the nape of the neck. The mice were randomly divided into two treatment groups, 8 in each group. On the day after implantation, in a solution containing 2.7mM KCl, 1mM KH 2 PO 4 , 137mM NaCl and 20mM Na 2 HPO 4 After dilution of the diluent from the stock concentrate, each group was administered intraperitoneally with 10 mg / kg AR90A56.11 detection antibody or buffer control in a volume of 300 microliters. The antibodies and control samples were then administered in the same manner 3 times per week for the duration of the study. Tumor growth was measured approximate...
PUM
Login to View More Abstract
Description
Claims
Application Information
- IPC
- C12N5/18; C07K16/30; A61K39/395; C07K16/46; A61K47/48; C07K19/00; A61K51/10; C12N5/16; A61P35/00; C12P21/08; A61P37/04; G01N33/574; C07K16/18; G01N33/577
- CPC
- A61K47/4843; G01N33/5017; A61K47/48569; A61K2039/505; G01N33/57492; A61K47/48423; A61K51/1045; C07K16/30
- Inventors
- 戴维·S·F·扬; 海伦·P·芬德利